PLCG1 and angioimmunoblastic T-cell lymphoma: In AITL cases, RHOA, TET2, IDH2, PLCG1 and DNMT3A were mutated in 35.1% (20/57), 29.8% (17/57), 14.03% (8/57), 14.03% (8/57) and 8.8% (5/57) of the cases, respectively (Figure 2).